Bhagiradha Chemicals Q4 FY26: Growth Returns, but the Margin Story Turns Complex

Bhagiradha Chemicals and Industries Limited closed FY26 with a clear recovery in scale and operating profit, even as the quarter highlighted how sensitive earnings remain to commissioning-linked costs and product mix shifts. On a consolidated basis, revenue from operations rose to 535.9 crores in FY26 from 440.5 crores in FY25, a 22 percent increase. EBITDA expanded faster, up 55 percent to 57.1 crores, as better realizations and higher utilization improved operating leverage. Profit after tax grew 31 percent to 18.2 crores.

The fourth quarter delivered the strongest revenue print of the year. Q4 FY26 revenue reached 158.1 crores versus 122.6 crores in Q4 FY25 and 114.0 crores in Q3 FY26. EBITDA also improved sharply year on year, rising to 19.4 crores from 6.1 crores. PAT turned positive at 4.1 crores compared with a loss of 0.9 crores in Q4 FY25. But the quarter also showed an unusual divergence between absolute EBITDA and reported margin trends across slides, reinforcing that investors should read the quarter in the context of shifting cost structure and the ramp-up of the Bheema facility.

Management’s framing for FY26 was steady progress supported by improving domestic demand, better volumes, and stronger execution. Realizations improved across certain product categories and were stable in a few molecules, while input costs, especially crude-linked derivatives affected by the West Asia conflict, remained a key variable.

FY26 performance: a volume and realization recovery

The company attributed FY26 growth to two levers working together. Volumes improved with better demand trends, and price realizations were better than last year. Management noted that some products moved closer to peak realization levels, while recovery in certain products is expected to be gradual. This matters because the last few years show how quickly profitability can soften when realization or cost cycles move against manufacturers.

Gross margin in FY26 improved modestly to 37.5 percent from 36.9 percent in FY25, while EBITDA margin expanded to 10.7 percent from 8.4 percent. The solar project, which commenced from April 2025, contributed by lowering power and fuel costs, which reduced to 8 percent of sales in FY26 from 10 percent in FY25.

Below EBITDA, FY26 profitability was supported by better operating performance, but moderated by higher depreciation and finance costs linked to the commissioning and capitalization at Bheema Fine Chemicals. Depreciation and amortization rose to 20.9 crores in FY26 from 13.9 crores in FY25, while interest expense increased to 17.5 crores from 7.1 crores.

A dividend recommendation also signaled management’s intent to balance growth spending with shareholder returns. For FY26, the board recommended a final dividend of 0.15 rupees per equity share of face value 1 rupee, subject to shareholder approval.

Financial summary table

Q4 FY26: strong revenue, mixed margin signals

Q4 FY26 was defined by a surge in revenue and a sharp year on year improvement in EBITDA and PAT. Consolidated revenue from operations grew 29 percent year on year to 158.1 crores and 39 percent sequentially from Q3 FY26. EBITDA rose to 19.4 crores from 6.1 crores in Q4 FY25, supported by improved realizations, operating efficiency, and process improvement. PAT improved year on year to 4.1 crores.

On costs, the quarter benefited from tapering raw material prices, excluding crude-linked derivatives. Gross margin improved to 38.9 percent from 31.7 percent in Q4 FY25. Management also highlighted favorable product mix and better pricing as drivers of realizations.

But the quarter’s margin narrative needs careful reading. One slide shows an EBITDA margin of 4.0 percent for Q4 FY26, while the profit and loss table shows 12.3 percent for Q4 FY26. Regardless of presentation differences, investors should focus on the underlying moving parts highlighted across the deck. Depreciation and interest are rising as new assets get commissioned, and the ramp-up phase tends to carry inefficiencies until utilization stabilizes.

Working capital also continues to matter. Working capital days were 150 in FY26, with debtor days rising to 97 from 68 in FY25, while inventory days increased to 96 from 94.

Balance sheet and cash flow: capex shows up in leverage and cash

FY26 was a capex-heavy year, and the balance sheet and cash flow statement reflect this clearly. Total assets increased to 1,120.2 crores as of March 2026 from 933.2 crores in March 2025. This was driven by a sharp rise in property, plant and equipment to 573.9 crores from 238.2 crores, while capital work in progress reduced to 94.2 crores from 287.8 crores as projects moved from construction to capitalization.

The liability mix shifted alongside commissioning. Non-current borrowings increased to 153.1 crores from 30.0 crores, and current borrowings rose to 77.9 crores from 54.4 crores. Debt to equity rose to 0.3 in FY26 from 0.1 in FY25.

Cash flows show the same investment cycle. Net cash from operating activities turned positive at 12.0 crores in FY26 compared with negative 52.8 crores in FY25, helped by improvement in working capital changes. But investing cash outflow remained large at 160.2 crores, reflecting continued capex. Financing cash inflow was 136.3 crores.

Returns are still depressed because the asset base has expanded faster than revenue in the near term. Asset turnover ratio declined to 0.8 in FY26 from 1.3 in FY25. Return on capital employed was 4 percent, and return on equity was 2.6 percent, both weighed down by the capital deployed into the Bheema Fine Chemicals plant over the last two years.

Strategy and execution: BCIL 2.0 rests on capacity, integration, and R&D

Bhagiradha Chemicals positions itself as a long-standing agrochemical active ingredient and intermediate player with 30 plus years of operating history, backed by in-house R&D and backward integration. The company reported an established product capability of 35 products in FY26 and emphasized regular product launches and a steady broadening of revenue contribution beyond the top five products. The top five products’ revenue contribution reduced to 81 percent in FY26 from 85 percent in FY25 and 95 percent in FY23, suggesting a gradual diversification of the product basket.

Customer concentration is managed with a stated cap where no single customer contributes more than 20 percent of sales. The number of customers increased to 149 in FY26 from 130 in FY25. Top five customer contribution was 35 percent in FY26.

R&D is presented as a growth engine. The company’s R&D center is approved by the Department of Scientific and Industrial Research and has eight synthesis labs with 60 plus chemists. The deck describes synthesis, kilo lab, process safety work, a pilot plant capable of scaling up to 25 kg per batch, and a semi-commercial plant producing up to 250 kg per batch to support early campaigns and registration sample needs. The strategic intent is to develop off-patent and upcoming off-patent molecules, build cost-effective non-infringing processes, and push backward integration deeper to match leading global active ingredient players.

The capex anchor for BCIL 2.0 is the 100 percent subsidiary, Bheema Fine Chemicals Private Limited, incorporated in July 2020 in Karnataka and which commenced commercial production on 27 March 2024. Phase I of the Bheema Fine project was successfully commenced, with capitalization of 400 crores during FY26. Phase 1B commenced in Q3 FY26 with a 12 to 24 month ramp-up timeline, and Phase 2 is expected to commence in Q2 FY28, with a similar ramp-up period.

The expansion program is described as 850 plus crores, including land of 34 acres, installed capacity of 9,002 MT with two processing blocks, automated operations through distributed control systems, zero liquid discharge, and a solar power plant to reduce power cost.

Operationally, capacity utilization at the standalone facility was about 92 percent in FY26. The deck notes that the Karnataka plant’s Phase 1 utilization was around 35 percent, and only for a quarter, which helps explain why near-term return ratios and operating metrics remain under pressure.

What to watch: ramp-up, cost pass-through, and return recovery

Management’s outlook for FY27 centers on a meaningful ramp-up in operations and unlocking full revenue potential alongside improved profitability. The company also acknowledged that the sharp increase in input costs witnessed in previous periods has not yet been fully offset through finished product price increases. That comment is important for margin durability. If realizations improve further while raw materials remain stable, operating leverage can be powerful, especially with the new capacity coming online. But if crude-linked derivatives stay elevated due to geopolitical factors, profitability could remain volatile.

The deck links margin support to multiple levers: better realizations, improved capacity utilization, process upgrades, and lower power and fuel costs due to the solar project. The same deck highlights the countervailing forces: higher depreciation and finance costs linked to commissioning, and the need to absorb a larger fixed asset base while ramping utilization.

BCIL 2.0 is therefore an execution story. The investment cycle is largely visible in the numbers, with rising PPE, higher borrowings, and lower asset turnover. The payoff depends on how quickly the new plant moves from early utilization to steady-state production and how successfully the company can increase backward integration and add higher-margin molecules.

The broader theme for FY26 is strategic clarity with transitional financials. Bhagiradha Chemicals delivered a strong recovery in revenue and EBITDA, expanded margins at the full-year level, and turned operating cash flow positive. Now the focus shifts to converting the expanded capacity and R&D pipeline into higher throughput and better returns, while managing input cost volatility and working capital discipline.